Company Registration No. 04308175 (England and Wales)	
OXFORD BIOMATERIALS LIMITED	
ABBREVIATED ACCOUNTS	
FOR THE YEAR ENDED 29 FEBRUARY 2016	
FOR THE TEAR ENDED 29 FEBRUART 2010	

CONTENTS

	Page	
Abbreviated balance sheet	1	
Notes to the abbreviated accounts	2 - 4	

ABBREVIATED BALANCE SHEET

AS AT 29 FEBRUARY 2016

		201	16	20 ⁻ as resta	
	Notes	£	£	£	£
Fixed assets					
Intangible assets	2		63,125		62,448
Tangible assets	2		3,410		7,082
Investments	2		3,001		3,001
			69,536		72,531
Current assets					
Debtors		4,546,921		4,542,002	
Cash at bank and in hand		127,174		177,484	
		4,674,095		4,719,486	
Creditors: amounts falling due within or	ne e				
year		(23,278)		(44,731) ————	
Net current assets			4,650,817		4,674,755
Total assets less current liabilities			4,720,353		4,747,286
Capital and reserves					
Called up share capital	3		1,809		1,809
Share premium account			510,556		510,556
Profit and loss account			4,207,988		4,234,921
Shareholders' funds			4,720,353		4,747,286

For the financial year ended 29 February 2016 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

These abbreviated financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

Approved by the Board for issue on 26 November 2016

Dr David Bott

Director

Company Registration No. 04308175

NOTES TO THE ABBREVIATED ACCOUNTS FOR THE YEAR ENDED 29 FEBRUARY 2016

1 Accounting policies

1.1 Accounting convention

The financial statements are prepared under the historical cost convention and in accordance with the Financial Reporting Standard for Smaller Entities (effective January 2015).

1.2 Turnover

Turnover represents amounts receivable for goods and services net of VAT and trade discounts.

1.3 Patents

Patents are valued at cost less accumulated amortisation. Amortisation is calculated to write off the cost in equal annual instalments over their estimated useful lives.

1.4 Tangible fixed assets and depreciation

Tangible fixed assets are stated at cost less depreciation. Depreciation is provided at rates calculated to write off the cost less estimated residual value of each asset over its expected useful life, as follows:

Plant and machinery 50% straight line on cost
Computer equipment 33% straight line on cost
Fixtures, fittings & equipment 25% straight line on cost

1.5 Investments

Fixed asset investments are stated at cost less provision for diminution in value.

1.6 Foreign currency translation

Monetary assets and liabilities denominated in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are recorded at the rate ruling at the date of the transaction. All differences are taken to profit and loss account.

NOTES TO THE ABBREVIATED ACCOUNTS (CONTINUED) FOR THE YEAR ENDED 29 FEBRUARY 2016

2	Fixed assets				
		Intangibl e Tang	Intangible assets li		Total
		assets			
		£	£	£	£
	Cost				
	At 1 March 2015	62,448	22,655	3,001	88,104
	Additions	6,916	4,490	=	11,406
	Disposals	-	(5,526)	-	(5,526)
	At 29 February 2016	69,364	21,619	3,001	93,984
	Depreciation				
	At 1 March 2015	-	15,575	=	15,575
	On disposals	-	(5,526)	-	(5,526)
	Charge for the year	6,239	8,160	-	14,399
	At 29 February 2016	6,239	18,209		24,448
	Net book value				
	At 29 February 2016	63,125	3,410	3,001	69,536
	At 28 February 2015	62,448	7,082	3,001	72,531

Holdings of more than 20%

The company holds more than 20% of the share capital of the following companies:

Company	Country of registration or	Shares held	
	incorporation	Class	%
Subsidiary undertakings			
Neurotex Limited	England and Wales	Ordinary shares	
			100.00

The aggregate amount of capital and reserves and the results of these undertakings for the last relevant financial year were as follows:

		Capital and reserves
		July 2015
	Principal activity	£
Neurotex Limited	Research and development into natural sciences	(12,669)

NOTES TO THE ABBREVIATED ACCOUNTS (CONTINUED) FOR THE YEAR ENDED 29 FEBRUARY 2016

3	Share capital	2016 £	2015 £
	Allotted, called up and fully paid		
	180,900 Ordinary shares of 1p each	1,809	1,809

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.